282 results on '"Radivoyevitch, T."'
Search Results
2. The relationship between eligibility criteria and adverse events in randomized controlled trials of hematologic malignancies
3. Adding molecular data to prognostic models can improve predictive power in treated patients with myelodysplastic syndromes
4. Molecular predictors of response in patients with myeloid neoplasms treated with lenalidomide
5. Incorporation of molecular data into the Revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes
6. GFI1 as a novel prognostic and therapeutic factor for AML/MDS
7. Defining AML and MDS second cancer risk dynamics after diagnoses of first cancers treated or not with radiation
8. Clinical and biological implications of ancestral and non-ancestral IDH1 and IDH2 mutations in myeloid neoplasms
9. p53 Independent epigenetic-differentiation treatment in xenotransplant models of acute myeloid leukemia
10. SBML Level 3: an extensible format for the exchange and reuse of biological models
11. On target cell numbers in radiation-induced H4-RET mediated papillary thyroid cancer
12. Biologically based risk estimation for radiation-induced CML: Inferences from BCR and ABL geometric distributions
13. Time course solutions of the Sax-Markov binary eurejoining/misrejoining model of DNA double-strand breaks
14. Estimation of the target stem-cell population size in chronic myeloid leukemogenesis
15. 142 - Increased Risk of Developing Myeloid Neoplasms, Including Myelodysplastic Syndrome, in Well-Differentiated Thyroid Cancers Treated with Radioactive Iodine
16. The death-mutation model of carcinogenesis
17. Bleeding Rates and Risk Factors among Cancer and Non-Cancer Patients; A Comparison of Several Anticoagulants
18. Treatment Outcomes of Cancer Associated Venous Thrombosis; The Cleveland Clinic Experience
19. Risk of developing chronic myeloid neoplasms in well-differentiated thyroid cancer patients treated with radioactive iodine
20. A novel genetic and morphologic phenotype of ARID2-mediated myelodysplasia
21. Distinct clinical and biological implications of various DNMT3A mutations in myeloid neoplasms
22. Risk of developing acute myeloid leukemia (AML) in well-differentiated thyroid cancer (WDTC) patients treated with radioactive iodine (RAI): a population-based study
23. Ancestral Events Including Germline and Somatic Mutations Determine Subclonal Events and Affect Phenotype of Progression in MDS
24. TET2 is Iron-Dependent so its Activity may be Compromised in SF3B1 Mutated Age-Related Clonal Hematopoiesis of Indeterminate Potential
25. Increased Risk of Developing Myeloid Neoplasms, Including Myelodysplastic Syndrome, in Well-Differentiated Thyroid Cancers Treated with Radioactive Iodine
26. Targeting the Oncogenic Node of Hedgehog Signaling in MDS
27. Dissectioning Risk Factors for Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) after Autotransplants for Plasma Cell Myeloma and Lymphomas
28. Adding Molecular Data to Prognostic Models can Improve their Predictive Power in Treated Patients with Myelodysplastic Syndromes (MDS)
29. Autotransplants for Lymphoid Neoplasms Increase the Risks of MDS More Than AML
30. Autophagy Stimulation Improves Erythroid Proliferative Capacity in Models of SF3B1 Mutant MDS
31. Two Mutations can Explain CMML Incidence Age Dependence if Models Consider Intermediate Cell Clonal Expansion
32. Targeting the Oncogenic Nexus of SETBP1-Set-PP2A by Structure Guided Small Molecule Design and Fragment Based Chemical Synthesis
33. Myeloid Cancer Mutation Rates Depend on Prior Cancer Therapies
34. Etiology and treatment of hematological neoplasms: Stochastic mathematical models
35. The complexity of interpreting genomic data in patients with acute myeloid leukemia
36. The relationship between eligibility criteria and adverse events in randomized controlled trials of hematologic malignancies
37. Radioprotection of IDH1-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198
38. Genomic patterns associated with hypoplastic compared to hyperplastic myelodysplastic syndromes
39. BRCC3 mutations in myeloid neoplasms
40. 20 SOMATIC MUTATIONAL MODEL TO PREDICT RESPONSE TO HYPOMETHYLATING AGENTS IN MYELODYSPLASTIC SYNDROMES
41. 79 RISK OF MYELODYSPLASTIC SYNDROMES IN WELL-DIFFERENTIATED THYROID CANCERS TREATED WITH RADIOACTIVE IODINE
42. 996O - Risk of developing acute myeloid leukemia (AML) in well-differentiated thyroid cancer (WDTC) patients treated with radioactive iodine (RAI): a population-based study
43. 291 - Autotransplants for Lymphoid Neoplasms Increase the Risks of MDS More Than AML
44. 202 - Targeting the Oncogenic Nexus of SETBP1-Set-PP2A by Structure Guided Small Molecule Design and Fragment Based Chemical Synthesis
45. 201 - Targeting the Oncogenic Node of Hedgehog Signaling in MDS
46. 76 - Two Mutations can Explain CMML Incidence Age Dependence if Models Consider Intermediate Cell Clonal Expansion
47. 61 - Dissectioning Risk Factors for Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) after Autotransplants for Plasma Cell Myeloma and Lymphomas
48. 55 - Myeloid Cancer Mutation Rates Depend on Prior Cancer Therapies
49. 53 - Autophagy Stimulation Improves Erythroid Proliferative Capacity in Models of SF3B1 Mutant MDS
50. 50 - Adding Molecular Data to Prognostic Models can Improve their Predictive Power in Treated Patients with Myelodysplastic Syndromes (MDS)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.